Home » Posts tagged with » Novartis (Page 3)
Novartis’ heart failure drug Entresto can be initiated early in hospitalized patients

Swiss drugmaker Novartis unveiled new data on Entresto (sacubitril/valsartan) from a phase 4 study which confirms that the heart failure drug can be initiated early and safely across a broad range of heart failure patients with reduced ejection fraction (HFrEF), whose condition has been stabilized following hospitalization because of an acute heart failure episode. In […]

Continue reading …
Hyrimoz EC approval : Novartis biosimilar of AbbVie Humira approved in EU

Hyrimoz EC approval : Novartis’ Sandoz has bagged approval for Hyrimoz (adalimumab), a biosimilar of AbbVie’s Humira (adalimumab), in Europe for all indications of the reference drug including rheumatoid arthritis, Crohn’s disease, plaque psoriasis, uveitis and ulcerative colitis. The approval of Hyrimoz by European Commission (EC) was driven by analytical, preclinical and clinical research that […]

Continue reading …
Novartis to in-license atopic dermatitis drug MOR106 from MorphoSys, Galapagos

Novartis has agreed to acquire the exclusive global development and marketing rights of atopic dermatitis drug MOR106 from MorphoSys and Galapagos in a deal that could go up to $1.1 billion. The Swiss drugmaker will make an upfront payment of €95 million ($111 million) to Galapagos and MorphoSys apart from potential milestone payments of up […]

Continue reading …
Novartis lung cancer drug Zykadia gets US FDA priority review

Swiss pharma Novartis has announced that its lung cancer drug Zykadia (ceritinib) has been granted the FDA priority review for its expanded use as the first-line treatment for lung cancer patients with certain conditions. The expanded use is for metastatic non-small cell lung cancer (NSCLC) patients whose tumors were detected by an approved FDA test […]

Continue reading …
Page 3 of 3123